{
    "clinical_study": {
        "@rank": "111195", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating women who have\n      advanced or recurrent cancer of the cervix."
        }, 
        "brief_title": "DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix", 
        "completion_date": {
            "#text": "September 2003", 
            "@type": "Actual"
        }, 
        "condition": "Cervical Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms, Squamous Cell", 
                "Uterine Cervical Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the antitumor activity of DX-8951f in women with advanced or recurrent\n           squamous cell carcinoma of the cervix.\n\n        -  Evaluate the quantitative and qualitative toxic effects of this regimen in these\n           patients.\n\n        -  Evaluate the pharmacokinetics of this regimen in these patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive DX-8951f IV over 30 minutes daily for 5 days. Courses repeat every 21 days\n      in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 3 months until death.\n\n      PROJECTED ACCRUAL: Approximately 37 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed advanced or recurrent squamous cell carcinoma of the cervix\n             not curable by surgery or radiotherapy\n\n          -  Measurable disease\n\n          -  No known brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  At least 12 weeks\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,500/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  SGOT or SGPT no greater than 2 times upper limit of normal (ULN) (5 times ULN if\n             liver metastases present)\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n        Cardiovascular:\n\n          -  No active congestive heart failure\n\n          -  No uncontrolled angina\n\n          -  No myocardial infarction within the past 6 months\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No concurrent serious infection\n\n          -  No other malignancy within the past 5 years except nonmelanomatous skin cancer\n\n          -  No other life threatening illness\n\n          -  No psychosis, mental disability, or incompetence\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No concurrent biologic therapy\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy\n\n          -  No more than 1 prior chemotherapy regimen (except chemotherapy for\n             radiosensitization)\n\n          -  No prior camptothecin\n\n          -  No other concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  At least 4 weeks since prior surgery\n\n          -  No concurrent surgery\n\n        Other:\n\n          -  At least 4 weeks since other prior investigational drugs (including analgesics or\n             antiemetics)\n\n          -  No other concurrent investigational drugs during or within 28 days after final dose\n             of study drug\n\n          -  No concurrent drugs that induce or inhibit CYP3A enzyme"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 7, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004866", 
            "org_study_id": "CDR0000067525", 
            "secondary_id": [
                "DAIICHI-8951A-PRT015", 
                "MDA-DM-99247"
            ]
        }, 
        "intervention": {
            "intervention_name": "exatecan mesylate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Exatecan", 
                "Camptothecin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage III cervical cancer", 
            "stage IV cervical cancer", 
            "recurrent cervical cancer", 
            "cervical squamous cell carcinoma"
        ], 
        "lastchanged_date": "May 15, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/DAIICHI-8951A-PRT015"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10461"
                    }, 
                    "name": "Albert Einstein Clinical Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10019"
                    }, 
                    "name": "St. Luke's-Roosevelt Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43614"
                    }, 
                    "name": "Ruppert Health Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Brookview Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Texas Oncology PA (TOPA) at Baylor-Sammons"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas - MD Anderson Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix", 
        "overall_official": {
            "affiliation": "Daiichi Sankyo Inc.", 
            "last_name": "Robert L. DeJager, MD, FACP", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004866"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }, 
    "geocoordinates": {
        "Albert Einstein Clinical Cancer Center": "40.85 -73.867", 
        "Brookview Research, Inc.": "36.166 -86.784", 
        "Ruppert Health Center": "41.664 -83.555", 
        "St. Luke's-Roosevelt Hospital": "40.714 -74.006", 
        "Texas Oncology PA (TOPA) at Baylor-Sammons": "32.803 -96.77", 
        "University of Texas - MD Anderson Cancer Center": "29.76 -95.369"
    }
}